Next-Gen Psoriasis Therapies:

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Systemic Lupus Erythematosus

Clinical Trials in IBD.

New Psoriasis Treatments

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

Treatment Algorithms in Melanoma: Past, Present, and Future

Unraveling Clinical Developments in NASH

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Dual Antiretroviral Therapy

Progression After Cancer Immunotherapy in Advanced NSCLC

From Conference to Practice: Big Data in Psoriasis

Atopic Dermatitis Treatment Landscape

Mid-Year Hemophilia Update

Atopic Dermatitis Treatment Landscape

Induction Chemotherapy for Patients With High-Risk or Secondary AML

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Novel Approaches in T1D Management

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Developments in the Wet AMD Treatment Landscape

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Advances in Severe Asthma Management

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

Evaluating BTK Inhibitors in CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

How to Select Therapy in Relapsed/Refractory CLL

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

You Don't Know JAK in IBD.

Presentation transcript:

Next-Gen Psoriasis Therapies:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Psoriasis Basics

Pathogenesis of Psoriasis

Pathogenesis of Psoriasis TNF-α

Pathogenesis of Psoriasis Interleukins

Targeted Agents for Psoriasis

PDE4 Inhibitor

IL-17 and IL-17 Receptor Blockers

IL-23 Blockers

JAK Inhibitors

Psoriasis Treatment and Its Effect on Outcomes: Efficacy

Safety Considerations IL-17 Inhibition

Safety Considerations IL-12 and IL-23 Inhibition

Newer Biologics Have Less Toxicity Compared With Older Systemic Agents

Who Would Benefit From Newer Targeted Agents?

Who Would Benefit From Newer Targeted Agents? (cont)

Who Would Benefit From Newer Targeted Agents? (cont)

Who Would Benefit From Newer Targeted Agents? (cont)

Who Would Benefit From Newer Targeted Agents? (cont)

Psoriasis and Cardiovascular Disease

Other Potential Considerations

Other Potential Considerations (cont)

Concluding Remarks

Abbreviations

Abbreviations (cont)